UF startup OxThera AB, a privately-held Stockholm-based biopharmaceutical company dedicated to improving the lives of people living with Primary Hyperoxaluria (PH), announced continuous strong data from a two-year interim analysis of its Phase 2 study with Oxabact® in PH.
OC5-OL-01 is the longest efficacy and safety study of any intervention to lower the oxalate burden in patients with PH. The two-year interim analysis shows continuous reductions in Pox (level of oxalate in the blood plasma) of – 40% (-67 µmol/L) compared with baseline. In addition, a normalization in cardiac function was observed in the patients.
“We are pleased to present results that show continuous clinically relevant reductions in Pox. We are excited about the potential of Oxabact in helping patients with this devastating disease,” says Matthew Gantz, CEO of OxThera.Learn more about Oxthera Presents Continuous Strong Data from an Interim Analysis of Its Phase 2 Study with Oxabact in Primary Hyperoxaluria.